Pharmabiz2m
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...
Pharmabiz33m
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...
Pharmabiz1h
Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury
Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...
Pharmabiz2h
Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel
Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel: Boulder, Colorado Wednesday, November 13, 2024, 16:00 Hrs [IST] Sonoma Pharmaceuticals, Inc.
Pharmabiz2h
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...
Pharmabiz3h
KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1
KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...
Pharmabiz4h
US FDA grants breakthrough therapy designation to Johnson & Johnson’s nipocalimab to treat adults living with moderate-to-severe Sjögren's disease
Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe ...
Pharmabiz5h
Merck to present new data from Gardasil 9 studies reinforcing the importance of gender-neutral HPV vaccination in adults up to age 45 at IPVC 2024
Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...
Pharmabiz5h
Vitonnix UK joins SEARCH Foundation in its mission to target the vitamin D deficiency endemic in rural India
Our Bureau, Mumbai Wednesday, November 13, 2024, 12:15 Hrs [IST] ...
Pharmabiz7h
Transforming future eye care with AI in ophthalmology
Ophthalmology has emerged as a subject where artificial intelligence (AI) holds great promise. Major developments in artificial intelligence technology over the last five years have created new ...
Pharmabiz8h
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...
Pharmabiz9h
AstraZeneca to invest $3.5 billion in R&D and manufacturing in US
AstraZeneca to invest $3.5 billion in R&D and manufacturing in US: Cambridge, UK Wednesday, November 13, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical ...